<DOC>
	<DOCNO>NCT00310830</DOCNO>
	<brief_summary>The study assess effect bosentan pulmonary vascular resistance exercise capacity sickle cell disease ( SCD ) patient diagnose pulmonary arterial hypertension . It consist 3 phase : Screening , Treatment Follow-up . During Screening visit , study doctor decide patient meet study requirement . All potential patient diagnosis increase pulmonary artery pressure show right heart catheterization conduct shortly prior start study treatment . Patients ask perform exercise capacity test ( walk far possible 6 minute ) . Following Baseline visit , treatment phase consist 4 additional clinic visit good bad effect drug review exercise capacity test repeat . Patients treat 16 week . Blood sample collect every month , often , need . At end study , patient ask repeat right heart catheterization exercise capacity test . After completion study , patient option enrol long-term follow-up study patient receive active drug . Patients elect participate extension study follow safety assessment 28 day end study treatment .</brief_summary>
	<brief_title>Efficacy Safety Bosentan Sickle Cell Disease ( SCD ) Patients With Pulmonary Arterial Hypertension ( PAH )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Screening Criteria : 1 . Males females ≥ 12 year age document history SCD 2 . Patients symptomatic PAH associate shortness breath 3 . Patients tricuspid regurgitation jet ( TRJ ) velocity &gt; 2.9 m/sec base echo/Doppler conduct within 6 month prior randomization SCD crisis 4 . Signed write informed consent obtain patient patient 's parent/legal representative prior initiation study related procedure 1 . Patients hemoglobin ( Hb ) SS Hb S/β0 genotype Hb A ≤ 10 % 2 . Sixminute walk test ( 6MWT ) distance ≥ 150 ≤ 450 3 . PAH confirm right heart catheterization ( RHC ) perform study site within 3 month randomization visit define : Mean pulmonary arterial pressure ( mPAP ) ≥ 25 mmHg Pulmonary capillary wedge pressure ( PCWP ) ≤ 15 mmHg measure RHC leave ventricular end diastolic pressure ( LVEDP ) ≤ 15 mmHg measure leave heart catheterization , PCWP measurement reliable Pulmonary vascular resistance ( PVR ) rest ≥ 160 dyn.sec/cm5 4 . Women childbearing potential must negative result serum pregnancy test use reliable method contraception study treatment 3 month study treatment termination 1 . Left ventricular ejection fraction &lt; 40 % ( echo/Doppler ) 2 . Systolic blood pressure &lt; 85 mmHg 3 . Uncontrolled hypertension systolic blood pressure &gt; 160 mmHg and/or diastolic blood pressure &gt; 100 mmHg 4 . Forced expiratory volume 1 second divide force vital capacity ( FEV1/FVC ) &lt; 0.5 5 . Total lung capacity ( TLC ) &lt; 50 % normal predict value 6 . Significant cardiac disease : ischemic , valvular , constrictive 7 . Hemoglobin concentration &lt; 6.0 g/dL time randomization 8 . Acute liver disease 9 . Evidence cirrhosis portal hypertension liver ultrasound biopsy 10 . ALT ≥ 2 time upper limit normal ( ULN ) and/or albumin &lt; 2.8 g/dL 11 . Acute chronic impairment ( dyspnea ) , limit ability comply study requirement ( particular 6MWT ) , e.g. , angina pectoris , intermittent claudication , symptomatic hip osteonecrosis 12 . Vasoocclusive crisis ( VOC ) acute chest syndrome ( ACS ) within 2 week randomization 12 VOC and/or ACS within last 12 month 13 . Blood transfusion within 4 week prior randomization 14 . Illness life expectancy short 6 month 15 . HIV opportunistic infection 16 . Psychotic , addictive , disorder limit ability provide inform consent comply study requirement 17 . Pregnant lactate woman 18 . Recently start ( &lt; 8 week prior randomization ) plan , exercisebased cardiopulmonary rehabilitation program 19 . Bone marrow transplantation 20 . Treatment plan treatment another investigational drug within 3 month prior randomization 21 . Treatment pulmonary hypertension endothelin receptor antagonist , phosphodiesterase5 inhibitor , prostanoids ( exclude acute administration catheterization procedure test vascular reactivity ) within 3 month prior randomization Larginine within 1 week prior randomization 22 . Treatment calcineurininhibitors ( e.g. , cyclosporine A tacrolimus ) , sirolimus , fluconazole , amiodarone , miconazole glibenclamide ( glyburide ) within 1 week prior randomization 23 . Known hypersensitivity bosentan excipients</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>Pulmonary hypertension</keyword>
	<keyword>Sickle Cell Disease</keyword>
	<keyword>Sickle cell anemia</keyword>
	<keyword>ASSET</keyword>
	<keyword>ASSET-1</keyword>
</DOC>